Anesthesia · Neuromuscular BlockadeRegulatory Approvalregulatorymid-term

Lupin's Sugammadex Sodium ANDA214338 Receives Approval Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 6:30:37 AM

Assessment confidence: 56% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval status of Lupin's Sugammadex Sodium could significantly impact the competitive landscape in the anesthesia market. This development necessitates a reassessment of market share and pricing strategies for existing Sugammadex products. Regulatory context from FDA (FDA AP — SUGAMMADEX SODIUM (ORIG)) supports the near-term read. Assessment grounded in 12 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for Sugammadex products. The strongest clinical anchor is Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain (ClinicalTrials.gov), sub-indication match (nmus rehab). In nmus rehab, 8 regulatory and 1 competitive items passed relevance filtering for Lupin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Sugammadex Sodium under ANDA214368 (Humanexa Signals) — sub-indication match (nmus rehab); entity match (sugammadex). This approval status may enhance Lupin's position in the anesthesia market, competing against other generic and branded formulations of Sugammadex.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SUGAMMADEX SODIUM (ORIG) (FDA). Entity match (lupin); Regulatory pathway relevance (nda). The approval status indicates progress towards final approval, which could influence compliance and market entry timelines for Lupin's product.

Key Risks

Elevated medium regulatory exposure for Lupin could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Lupin's approval may lead to increased competition, potentially affecting revenue and market share for both branded and generic Sugammadex products.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for Sugammadex products.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timelines for ANDA214338.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from FDA Grants Approval for Sugammadex Sodium under ANDA214368 would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUGAMMADEX SODIUM (ORIG)
FDAmedium relevance
Entity match (sugammadex); Regulatory pathway relevance (nda)
FDA document
View source

Effect of Integrated Neuromuscular Inhibition Technique on Patients With Non-Specific Neck Pain
ClinicalTrials.govhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of Postoperative Hearing Loss After Spinal Anesthesia for Elective Cesarean Section in Pregnant Women
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Vibratory Anesthesia on Pain Following Corticosteroid Injections
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Grants Approval for Sugammadex Sodium under ANDA214368
Humanexa Signalshigh relevance
Sub-indication match (nmus rehab); Entity match (sugammadex)
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartislow relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartislow relevance
Sponsor/company relevance (Novartis)
FDA document
View source
FDA Approves Sugammadex Sodium for Gland Pharma
Humanexa Signalslow relevance
Entity match (sugammadex)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedhigh relevance
Sub-indication match (nmus rehab)
FDA document
View source
Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.
PubMedmedium relevance
Sub-indication match (nmus rehab)
FDA document
View source
Influence of Oliceridine on the Incidence of Postoperative Nausea and Vomiting in High-Risk Patients Stratified Using Apfel Score After General Anesthesia: A Prospective, Randomized Controlled Clinica
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Protocol for a cohort study: evaluating the effect of neoadjuvant immunochemotherapy on intraoperative remifentanil consumption during IoC2-guided anesthesia in elderly patients with esophageal cancer
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Targeting lymphotoxin β receptor: from mechanism to precision therapy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Lupin
Sugammadex

Commercial impact

medium

Lupin's approval may lead to increased competition, potentially affecting revenue and market share for both branded and generic Sugammadex products.

Regulatory impact

medium

The approval status indicates progress towards final approval, which could influence compliance and market entry timelines for Lupin's product.

What to watch

Monitor for the final approval and market launch timelines for ANDA214338.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.